<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37245" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Latanoprost</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Geetha</surname>
            <given-names>Ragi</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ragi Geetha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37245.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Latanoprost is an eye drop formulation helpful in the management of elevated intraocular pressure (IOP) within patients grappling with ocular hypertension or open-angle glaucoma. This prostaglandin F2 alpha analog is a frontline approach in glaucoma treatment, leveraging its proven efficacy in IOP reduction. Renowned for its convenience with a once-daily dosing regimen and an acceptable safety profile, prostaglandins like latanoprost have become the cornerstone of glaucoma therapy.</p>
        <p>The United States Food and Drug Administration (FDA) approved the fixed-dose combination of netarsudil/latanoprost in March 2019, expanding treatment options for those afflicted with open-angle glaucoma and ocular hypertension. Beyond its approved applications, latanoprost is utilized off-label for diverse glaucoma variants. This activity covers latanoprost's mechanism of action, pharmacology, indications, adverse event profiles, contraindications, toxicity, and the collaborative efforts of the interprofessional team essential in managing conditions where latanoprost proves therapeutically beneficial.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for latanoprost in the treatment of glaucoma and ocular hypertension.</p></list-item><list-item><p>Screen patients for contraindications and potential drug interactions before initiating latanoprost therapy.</p></list-item><list-item><p>Assess patients' response to latanoprost therapy by regularly monitoring intraocular pressure and evaluating treatment effectiveness.</p></list-item><list-item><p>Develop effective communication&#x000a0;with patients about latanoprost, explaining its benefits, potential side effects, and the importance of adherence.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37245&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37245">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37245.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Latanoprost is an FDA-approved eye drop formulation to treat elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.&#x000a0;The drug is a prostaglandin F2-alpha analog. Latanoprost reduces IOP by increasing the outflow of aqueous humor&#x000a0;and improving the uveoscleral outflow.<xref ref-type="bibr" rid="article-37245.r1">[1]</xref></p>
        <p>Prostaglandins are most commonly used as the first&#x000a0;line of treatment in glaucoma due to their efficacy in reducing the IOP, convenience of once-daily dosing, and acceptable safety profile. Latanoprost is the first prostaglandin analog approved by the&#x000a0;United States Food and Drug Administration (FDA). The drug was FDA-approved for ocular use in 1996.</p>
        <p>Additionally, the fixed-dose combination (FDC) of netarsudil/latanoprost&#x000a0;was approved by&#x000a0;the&#x000a0;USFDA in March 2019 for&#x000a0;open-angle glaucoma&#x000a0;(OAG) and&#x000a0;ocular hypertension&#x000a0;(OHT).<xref ref-type="bibr" rid="article-37245.r2">[2]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Latanoprost is used off-label for&#x000a0;different&#x000a0;variants of glaucoma.<xref ref-type="bibr" rid="article-37245.r3">[3]</xref>&#x000a0;These indications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric glaucoma</p>
          </list-item>
          <list-item>
            <p>Chronic angle-closure glaucoma</p>
          </list-item>
          <list-item>
            <p>Normal-tension glaucoma</p>
          </list-item>
          <list-item>
            <p>Steroid-induced glaucoma</p>
          </list-item>
          <list-item>
            <p>Pigmentary glaucoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-37245.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Prostaglandin synthesis occurs in the cell from arachidonic acid. Arachidonic acid, a 20-carbon molecule, gets metabolized to leukotrienes (LT) by lipoxygenases or converted to cyclic endoperoxides by cyclooxygenases. The cyclic endoperoxides are metabolized to prostaglandin F2-alpha (PGF2&#x003b1;) by prostaglandin synthase, reductase, and thromboxanes by thromboxane synthase.</p>
        <p>Prostaglandin, thromboxane, and leukotriene are called eicosanoids. Various receptors exist for eicosanoids, including DP (prostaglandin D), EP (prostaglandin E), FP (prostaglandin F), IP (prostaglandin I or prostacyclin receptor), and TP (prostaglandin T). FP receptor has 2 variants: type A (full-length variant) and type B (spliced variant). Both FP receptors act as G-protein-coupled receptors. FP receptors are expressed in multiple ocular tissues, including ciliary smooth muscles.&#x000a0;&#x000a0;</p>
        <p>Latanoprost is a&#x000a0;PGF2&#x003b1; analog (FP receptor agonist) that increases the uveoscleral outflow of the aqueous fluid. Other PGF2&#x003b1; analogs with the same mechanism of action are travoprost and tafluprost.<xref ref-type="bibr" rid="article-37245.r4">[4]</xref><xref ref-type="bibr" rid="article-37245.r5">[5]</xref> The proposed mechanisms include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Relaxation of ciliary smooth muscles</p>
          </list-item>
          <list-item>
            <p>Cytoskeletal alteration leads to changes in the shape of cells</p>
          </list-item>
          <list-item>
            <p>Remodeling of the extracellular matrix of the uveoscleral pathway by increased matrix metalloproteinases 
<list list-type="bullet"><list-item><p>PGF2&#x003b1; and latanoprost were noted to reduce collagen I, III, and 4, hyaluronans, fibronectin, and laminin, and increase matrix metalloproteinases 2 and 3 and plasmin in cultured ciliary smooth muscles.</p></list-item><list-item><p>In the animal model, researchers noted that topical PGF2&#x003b1; reduces the expression of TIGR (trabecular meshwork inducible glucocorticoid response gene) or MYOC (myocilin).</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Latanoprost is absorbed through the cornea. The isopropyl ester of latanoprost gets hydrolyzed by the cornea to the acid, which is the biologically active form. Studies in men indicate that the peak concentration in the aqueous humor is reached about&#x000a0;2 hours after topical administration. The maximum drug concentration in the aqueous humor is achieved 2 hours after topical use of the drop. The drug starts reducing IOP after 3 to 4 hours of administration, and the maximum IOP-lowering effect is seen 8 to 12 hours after use. The IOP-lowering effect lasts for more than 24 hours, allowing once-daily dosage.&#x000a0;</p>
        <p><bold>Distribution:</bold>&#x000a0;The distribution volume in humans is 0.16 &#x000b1; 0.02 L/kg. The solubility of latanoprost, travoprost, and unoprostone improves by adding isopropyl ester to the carboxyl-terminal of PGF2&#x003b1;. Adding a phenyl ring to the omega chain of PGF2&#x003b1; in the prostaglandin analogs (latanoprost, travoprost, bimatoprost) improves selectivity for the FP receptor.&#x000a0;In animal studies, topical&#x000a0;prostaglandin in high doses showed an initial IOP rise with a subsequent prolonged period (15 to 20 hours) of IOP reduction.&#x000a0;A high dose may also disrupt the blood-aqueous barrier and cause conjunctival hyperemia. On the other hand, low-dose topical PG causes prolonged IOP reduction only.<xref ref-type="bibr" rid="article-37245.r6">[6]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Latanoprost is an isopropyl ester prodrug. Esterases hydrolyze the prodrug in the cornea to the biologically active acid. The liver metabolizes the latanoprost reaching the systemic circulation to the 1,2-dinor and 1,2,3,4-tetranor by fatty acid &#x003b2;-oxidation.</p>
        <p><bold>Excretion:</bold>&#x000a0;Latanoprost elimination from human plasma is rapid (t<sub>1/2</sub> = 17 min) after intravenous and topical administration. Systemic clearance is 7 mL/min/kg. Following hepatic &#x003b2;-oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the given dose are recovered in the urine after topical and IV dosing.</p>
        <p>In animal studies, topical&#x000a0;prostaglandin&#x000a0;in high doses showed an initial IOP rise with a subsequent prolonged period (15 to 20 hours) of IOP reduction. A high dose may also disrupt the blood-aqueous barrier and cause conjunctival hyperemia. On the other hand, low-dose topical prostaglandin causes prolonged IOP reduction only.<xref ref-type="bibr" rid="article-37245.r6">[6]</xref></p>
      </sec>
      <sec id="article-37245.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Latanoprost is a colorless, isotonic ophthalmic solution available at a strength of 0.005%. According to the manufacturer,&#x000a0;unopened bottles should be refrigerated at 2&#x000a0;&#x000b0;C to 8 &#x000b0;C (36&#x000a0;&#x000b0;F to 46 &#x000b0;F) for storage. During shipping, the container may remain at temperatures up to 40 &#x000b0;C (104 &#x000b0;F) for a period not exceeding&#x000a0;8 days. Upon opening the bottle, it may be stored at room temperature up to 25 &#x000b0;C (77 &#x000b0;F) for&#x000a0;6 weeks.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The dosage is&#x000a0;1 drop once daily at night, and the IOP lowering effect reduces (or paradoxical IOP rise may occur) when used more than once daily.&#x000a0;The IOP lowering effect may be reduced due to subsensitivity at the FP receptors.<xref ref-type="bibr" rid="article-37245.r7">[7]</xref></p>
        <p>Latanoprost may be administered with other antiglaucoma agents to reduce intraocular pressure. If more than&#x000a0;1 topical ophthalmic drug is being used, there should be a minimum gap of 5 minutes between&#x000a0;each drop. Contact lenses&#x000a0;should be removed before administering the medication, and the patient should not reinsert them within 15 minutes of the topical application of the drop. Latanoprost administration is topical, with&#x000a0;1 drop once daily in the evening in the affected eye(s).</p>
        <p>The average IOP drop with latanoprost ranges from 30% to 35%. At&#x000a0;6 months, latanoprost was noted to reduce IOP by 35% when applied in the evening and 31% when instilled in the morning compared to timolol, which caused a 27% reduction in IOP.<xref ref-type="bibr" rid="article-37245.r8">[8]</xref>&#x000a0;A meta-analysis found that the mean IOP reduction (in mm Hg) with various antiglaucoma drugs was bimatoprost: 5.61, latanoprost: 4.85, travoprost: 4.83, levobunolol: 4.51, tafluprost: 4.37, timolol: 3.70, brimonidine: 3.59, carteolol: 3.44, levobetaxolol: 2.56, apraclonidine: 2.52, dorzolamide: 2.49, brinzolamide: 2.42, betaxolol: 2.24, and unoprostone: 1.91.<xref ref-type="bibr" rid="article-37245.r9">[9]</xref></p>
        <p>Once-daily latanoprost has been shown to achieve a uniform round-the-clock reduction of IOP either alone or combined with a twice-daily dose of timolol.<xref ref-type="bibr" rid="article-37245.r10">[10]</xref>&#x000a0;The dosage is once daily using a combination drop of latanoprost and timolol.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> There is&#x000a0;no information about dosage adjustments in patients with hepatic impairment in the manufacturer's labeling.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;There is&#x000a0;no information about dosage adjustments in patients with&#x000a0;renal impairment in the manufacturer's labeling.</p>
        <p><bold>Pregnancy considerations:</bold> This drug has been labeled FDA Category C.&#x000a0;Prostaglandins stimulate uterine smooth muscle, inducing uterine contractions, and animal studies have indicated an augmented risk of abortion or preterm delivery. In animal reproduction studies, intravenous (IV) administration of latanoprost to pregnant rabbits and rats throughout organogenesis resulted in embryofetal lethality, malformations, and spontaneous abortion at clinically relevant doses. There are no adequate and well-controlled studies of latanoprost ophthalmic solution administration in pregnant women to advise regarding drug-associated risks. However, theoretically, prostaglandins increase uterine tone and can lead to premature labor. Hence, other classes of medications than latanoprost should be selected to treat glaucoma during pregnancy.<xref ref-type="bibr" rid="article-37245.r11">[11]</xref><xref ref-type="bibr" rid="article-37245.r12">[12]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>No information on using latanoprost during breastfeeding is available. Because of the drug's short half-life, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Professional guidelines consider prostaglandin eye drops acceptable during breastfeeding. To diminish the amount of drug that reaches the breastmilk after using eye drops, the clinician should advise the patient to place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.<xref ref-type="bibr" rid="article-37245.r13">[13]</xref></p>
      </sec>
      <sec id="article-37245.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The primary adverse effects of latanoprost include eyelid edema, blurred vision, dry eyes, itching, redness, the growth of eyelashes, change in eyelid pigmentation (may become darker), iris, and eyelash.&#x000a0;Other&#x000a0;adverse effects of latanoprost include contact dermatitis/allergic conjunctivitis and an iris cyst.<xref ref-type="bibr" rid="article-37245.r14">[14]</xref>&#x000a0;See specific adverse effects listed below.&#x000a0;</p>
        <p><bold>Conjunctival hyperemia</bold>: Conjunctival hyperemia is among the most common side effects noted in 5% to 15% of patients, more than in timolol-treated eyes. Latanoprost with a preservative (benzalkonium chloride) may reduce the goblet cell density.<xref ref-type="bibr" rid="article-37245.r15">[15]</xref>&#x000a0;The conjunctival redness usually appears within 2 to 3 days of initiation of the topical treatment, reduces within&#x000a0;1 month, and is typically mild with prolonged use.</p>
        <p><bold>Hypertrichosis</bold>: Hypertrichosis is an increase in the thickness, length, and number of eyelashes. Although this is preferred from a cosmetic point of view in some patients, the unilateral occurrence can be undesirable. The changes in the eyelashes are usually reversible after discontinuing the drug; this is due to the stimulation of the growth phase of the hair cycle.<xref ref-type="bibr" rid="article-37245.r1">[1]</xref></p>
        <p><bold>Pigmentation</bold>: The pigmentation is due to increased melanin in the melanocytes, but the number of melanocytes does not increase. There is an upregulation of the tyrosinase activity in the melanocytes.<xref ref-type="bibr" rid="article-37245.r16">[16]</xref>&#x000a0;The pigmentation may increase for the duration of drug use. The brownish color change of the iris after latanoprost use is permanent, but the pigmentation of the eyelid, periorbital tissue, and eyelash may be reversible. The pigmentation of the iris usually starts around the pupillary margin and then spreads towards the peripheral iris. Iris nevi and freckles are not affected by latanoprost. The pigmentation of the iris usually begins within&#x000a0;1 year of therapy and continues to increase with the use of the drug. Patients should receive counsel regarding the possible change in iris color, which may be more evident if using the medicine in only&#x000a0;1 eye. The iris pigmentation is more common in light-colored rides but may also occur in dark or brown rides. Darkening of the iris occurs in up to 10% of cases.&#x000a0;Pigmentation of periocular tissue is reducible by removing the excess latanoprost drop from around the eye.<xref ref-type="bibr" rid="article-37245.r16">[16]</xref></p>
        <p><bold>Intraocular inflammation</bold>: Latanoprost may worsen intraocular inflammation (uveitis) and should be avoided in the actively inflamed eye.&#x000a0;</p>
        <p><bold>Macular edema</bold>: Latanoprost may induce or aggravate macular edema, including cystoid macular edema.&#x000a0;Patients with aphakia&#x000a0;and pseudophakia with open posterior capsules are at higher risk of developing cystoid macular edema (CME).<xref ref-type="bibr" rid="article-37245.r17">[17]</xref>&#x000a0;Prostaglandin analogs (PGA) related to CME can be treated with discontinuation of the PGA. The most commonly used treatment strategy in pseudophakic CME is to suppress postsurgical inflammation using topical NSAIDs or corticosteroids, separately or combined. Corticosteroids are frequently used to treat pseudophakic CME because of their well-known anti-inflammatory effects.<xref ref-type="bibr" rid="article-37245.r17">[17]</xref></p>
        <p><bold>Reactivation of herpetic keratitis</bold>: This may occur with latanoprost, and patients with active herpetic keratitis should avoid latanoprost.<xref ref-type="bibr" rid="article-37245.r18">[18]</xref>&#x000a0;A contaminated multidose vial of latanoprost may cause bacterial keratitis in patients with a corneal epithelial defect or other corneal diseases.</p>
        <p><bold>Superficial punctate keratopathy</bold>: Damage to the ocular surface, including reduced tear break-up time, superficial punctate keratopathy may occur due to the preservative in latanoprost (benzalkonium), and the ocular surface toxicity has been noted to be less with preservative-free tafluprost.<xref ref-type="bibr" rid="article-37245.r19">[19]</xref></p>
      </sec>
      <sec id="article-37245.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Latanoprost is contraindicated in patients with documented hypersensitivity&#x000a0;to the drug or components of the formulation, including latanoprost (the active ingredient) or benzalkonium chloride (preservative), sodium chloride, monobasic sodium phosphate, and dibasic sodium phosphate.</p>
      </sec>
      <sec id="article-37245.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitor for adverse drug reactions such as intraocular inflammation, pigmentary changes, and macular edema. Monitor intraocular pressure every 2 to 4 weeks until target intraocular pressure is attained. Subsequently, every&#x000a0;6 months is sufficient.&#x000a0;For&#x000a0;pediatric glaucoma, a&#x000a0;14-day home monitoring period provided a more than 90% chance of identifying an IOP spike.<xref ref-type="bibr" rid="article-37245.r20">[20]</xref></p>
      </sec>
      <sec id="article-37245.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Researchers found no carcinogenesis or mutagenesis with latanoprost, and&#x000a0;the drug did not affect fertility in animal studies. However, latanoprost was noted to cause a chromosomal aberration in treated human lymphocytes. Intravenous infusion of 3 &#x003bc;g/kg of latanoprost in healthy volunteers produced plasma concentrations 200 times higher than during clinical treatment with latanoprost ophthalmic solution, and researchers&#x000a0;identified no ADR. There&#x000a0;is no evidence to establish a correlation between latanoprost administration&#x000a0;and ocular or cutaneous melanoma.<xref ref-type="bibr" rid="article-37245.r21">[21]</xref></p>
        <p>Intravenous infusion of 5.5 to 10 &#x003bc;g/kg resulted in fatigue, sweating, dizziness, nausea, and abdominal pain. According to the manufacturer's labeling, treatment should be symptomatic if there is an overdosage with latanoprost ophthalmic solution.</p>
      </sec>
      <sec id="article-37245.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Latanoprost is a prostaglandin analog considered for the first-line management of open-angle glaucoma. Multiple randomized control trials have proven its efficacy in lowering IOP in primary open-angle glaucoma, similar to travoprost and bimatoprost, but the latanoprost may demonstrate better tolerability.<xref ref-type="bibr" rid="article-37245.r22">[22]</xref><xref ref-type="bibr" rid="article-37245.r1">[1]</xref>&#x000a0;</p>
        <p>Retinal examination for cystoid macular edema and ruling out active inflammation before starting the therapy is vital. Also, the IOP should be monitored regularly by the ophthalmologist and the ophthalmic specialty-trained nurse to ensure the medication works.&#x000a0;The pharmacist should educate the patient about the adverse effects of the drug, which may include darkening of the color of the iris, eyelids, periocular area, and eyelashes.<xref ref-type="bibr" rid="article-37245.r22">[22]</xref></p>
        <p>An interprofessional team approach is needed to provide comprehensive and collaborative care for the patient.&#x000a0;An ophthalmology-trained nurse and the pharmacist play a crucial role in assisting the&#x000a0;prescriber in achieving this goal. The nurse can&#x000a0;help educate the patient about the indication and expected outcomes of latanoprost therapy and the need for following up on IOP testing. The pharmacist can help the team by educating the patient about proper dosing, administration, storage, and adverse drug effects.</p>
      </sec>
      <sec id="article-37245.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37245&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37245">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37245/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37245">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37245.s11">
        <title>References</title>
        <ref id="article-37245.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alm</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Latanoprost in the treatment of glaucoma.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2014</year>
            <volume>8</volume>
            <fpage>1967</fpage>
            <page-range>1967-85</page-range>
            <pub-id pub-id-type="pmid">25328381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Serle</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>55</volume>
            <issue>9</issue>
            <fpage>563</fpage>
            <page-range>563-574</page-range>
            <pub-id pub-id-type="pmid">31584573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Digiuni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fogagnolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A review of the use of latanoprost for glaucoma since its launch.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>723</fpage>
            <page-range>723-45</page-range>
            <pub-id pub-id-type="pmid">22348427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ocklind</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections.</article-title>
            <source>Exp Eye Res</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-91</page-range>
            <pub-id pub-id-type="pmid">9733584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindsey</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Gaton</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Sagara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Polansky</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Reduced TIGR/myocilin protein in the monkey ciliary muscle after topical prostaglandin F(2alpha) treatment.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>8</issue>
            <fpage>1781</fpage>
            <page-range>1781-6</page-range>
            <pub-id pub-id-type="pmid">11431442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camras</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Bito</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Eakins</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>1977</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1125</fpage>
            <page-range>1125-34</page-range>
            <pub-id pub-id-type="pmid">924742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lind&#x000e9;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alm</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?</article-title>
            <source>Curr Eye Res</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>567</fpage>
            <page-range>567-72</page-range>
            <pub-id pub-id-type="pmid">9663846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stjernschantz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.</article-title>
            <source>Ophthalmology</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>102</volume>
            <issue>12</issue>
            <fpage>1743</fpage>
            <page-range>1743-52</page-range>
            <pub-id pub-id-type="pmid">9098273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lindsley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rouse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Wormald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dickersin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.</article-title>
            <source>Ophthalmology</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-40</page-range>
            <pub-id pub-id-type="pmid">26526633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000e1;cz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruzsonyi</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>ZT</given-names>
              </name>
              <name>
                <surname>Gaygi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bito</surname>
                <given-names>LZ</given-names>
              </name>
            </person-group>
            <article-title>Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>114</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-73</page-range>
            <pub-id pub-id-type="pmid">8600885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Razeghinejad</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma medications in pregnancy.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2018</year>
            <season>Sep-Dec</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-199</page-range>
            <pub-id pub-id-type="pmid">30505107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>DeOliveria</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ramulu</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Buys</surname>
                <given-names>YM</given-names>
              </name>
              <collab>American Glaucoma Society and the Canadian Glaucoma Society</collab>
            </person-group>
            <article-title>A Practical Guide to the Pregnant and Breastfeeding Patient with Glaucoma.</article-title>
            <source>Ophthalmol Glaucoma</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-89</page-range>
            <pub-id pub-id-type="pmid">32672600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Latanoprost</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>4</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Allergic contact dermatitis caused by topical eye drops containing latanoprost.</article-title>
            <source>Ann Dermatol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>269</fpage>
            <page-range>269-70</page-range>
            <pub-id pub-id-type="pmid">24882991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahook</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Noecker</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Quantitative analysis of conjunctival goblet cells after chronic application of topical drops.</article-title>
            <source>Adv Ther</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>743</fpage>
            <page-range>743-51</page-range>
            <pub-id pub-id-type="pmid">18670744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grierson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cracknell</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Latanoprost and pigmentation.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>2004</year>
            <season>Nov-Dec</season>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>602</fpage>
            <page-range>602-12</page-range>
            <pub-id pub-id-type="pmid">15592791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holl&#x000f3;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cantor</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Aihara</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2020</year>
            <season>Sep-Oct</season>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>496</fpage>
            <page-range>496-512</page-range>
            <pub-id pub-id-type="pmid">32092363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villegas</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Izquierdo</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic solutions: a case report.</article-title>
            <source>P R Health Sci J</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>348</fpage>
            <page-range>348-9</page-range>
            <pub-id pub-id-type="pmid">19069363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tokuda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kitaoka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuzawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsukamoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sakae</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.</article-title>
            <source>J Ophthalmol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>3540749</fpage>
            <pub-id pub-id-type="pmid">28831305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bitner</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Long-term home monitoring of intraocular pressure in pediatric glaucoma.</article-title>
            <source>J AAPOS</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>515</fpage>
            <page-range>515-518</page-range>
            <pub-id pub-id-type="pmid">27702611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tressler</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Wiseman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Dombi</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Jessen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Wirostko</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>95</volume>
            <issue>11</issue>
            <fpage>1490</fpage>
            <page-range>1490-5</page-range>
            <pub-id pub-id-type="pmid">21515566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37245.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parrish</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Palmberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sheu</surname>
                <given-names>WP</given-names>
              </name>
              <collab>XLT Study Group</collab>
            </person-group>
            <article-title>A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2003</year>
            <month>May</month>
            <volume>135</volume>
            <issue>5</issue>
            <fpage>688</fpage>
            <page-range>688-703</page-range>
            <pub-id pub-id-type="pmid">12719078</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
